Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-23 17:03 CEST (UTC+2h)

FDA Study Population Requirement for BE Studies: Ethics or Science [Regulatives / Guidelines]

posted by bebac_fan - US, 2018-05-15 20:57  - Posting: # 18767
Views: 472

Hi Obinoscopy,

Thanks for bringing this up for discussion. We can all think of many examples where PK in intended populations may be different than the general. However, it is hard to think of situations where a physiological state will selectively alter the PK of a test drug.

After thinking for a bit, and quite a bit of stretching, I could come up with gastric pH (e.g. increased in elderly) maybe affecting BA for a pH liable dispersion matrix. Perhaps other formulation dependent things for reduced GI motility. But I think this is in general a "feel good" clause and not scientifically rooted.

Cheers
BF

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,190 registered users;
online 15 (1 registered, 14 guests [including 8 identified bots]).

[The] impatience with ambiguity can be criticized in the phrase:
absence of evidence is not evidence of absence.    Carl Sagan

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed